TRELEGY ELLIPTA

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: d9b668ee1061c17d
Drug Approval Canada Name: TRELEGY ELLIPTA
Product Name: TRELEGY ELLIPTA
Status: Marketed
Status Date: 2021-09-13
Original Market Date: 2021-09-13
Din: 02515776
Drug Class: Human
Dosage Form: Powder
Route Of Administration: Inhalation
Schedule: Prescription
Ahfs: 12:12.08.12
Atc Original: R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE
Atc Name: r 03 al 08
Aig Number: 0360150002
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

FLUTICASONE FUROATE

200 MCG / ACT

UMECLIDINIUM (UMECLIDINIUM BROMIDE)

62.5 MCG / ACT

VILANTEROL (VILANTEROL TRIFENATATE)

25 MCG / ACT

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

d9b668ee1061c17d

Type

Standard